Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Taksim Ahmed; Fuh Ching Franky Liu; Brian Lu; Hoyin Lip; Elliya Park; Ibrahim Alradwan; Jackie Fule Liu; Chunsheng He; Abdulmottaleb Zetrini; Tian Zhang; Amin Ghavaminejad; Andrew M. Rauth; Jeffrey T. Henderson; Xiao Yu Wu

doi:10.1021/acs.molpharmaceut.2c00038

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Taksim Ahmed, Fuh Ching Franky Liu, Brian Lu, Hoyin Lip, Elliya Park, Ibrahim Alradwan, Jackie Fule Liu, Chunsheng He, Abdulmottaleb Zetrini, Tian Zhang, Amin Ghavaminejad, Andrew M. Rauth, Jeffrey T. Henderson, Xiao Yu Wu^*

^*Corresponding author for this work

Biomedical Engineering

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. First-hand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine- and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.

Original language	English (US)
Pages (from-to)	1722-1765
Number of pages	44
Journal	Molecular Pharmaceutics
Volume	19
Issue number	6
DOIs	https://doi.org/10.1021/acs.molpharmaceut.2c00038
State	Published - Jun 6 2022

Funding

This work is supported in part by the Weston Brain Institute Transformational Grant, University of Toronto Connaught Innovation Award, Killam Research Fellowship by the Canada Council for the Arts, Project Grants from the Canadian Institutes of Health Research, Discovery and Equipment Grants from the Natural Sciences and Engineering Research Council of Canada, JDRF International, and Hemsley Charitable Trust Grants to X.Y.W. The authors also acknowledge the University of Toronto Connaught International Scholarship for Doctoral Students and the Pfizer Canada Graduate Fellowship in Pharmaceutical Sciences to T.A., the Centre for Collaborative Drug Research Graduate Student Incentive Fund to X.Y.W., the Ontario Graduate Scholarship (OGS) to B.L. and T.Z., the Queen Elizabeth Award to B.L. and H.Y.L., the Pharmaceutical Sciences Graduate Student Association Fellowship to E.P., King Abdulaziz City for Science and Technology (KACST) for the scholarship to I.A., Libyan Ministry of Higher Education scholarship to A.Z., Mitacs Accelerate Intership to F.J.L., the BBDC Seller Fellowship to A.GN., and the Mitacs Accelerate Fellowship to K.C.

Keywords

blood-brain barrier (BBB)-penetrating
multitargeted drug delivery
nanomedicine
polymer lipid hybrid nanoparticles (PLN)
stimulus-responsive drug release
synergistic drug combination
tumor microenvironment modulation

ASJC Scopus subject areas

Drug Discovery
Molecular Medicine
Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acs.molpharmaceut.2c00038

Cite this

@article{cb948da45bd14a64aebea6eea2e43935,

title = "Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs",

abstract = "Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. First-hand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine- and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.",

keywords = "blood-brain barrier (BBB)-penetrating, multitargeted drug delivery, nanomedicine, polymer lipid hybrid nanoparticles (PLN), stimulus-responsive drug release, synergistic drug combination, tumor microenvironment modulation",

author = "Taksim Ahmed and Liu, {Fuh Ching Franky} and Brian Lu and Hoyin Lip and Elliya Park and Ibrahim Alradwan and Liu, {Jackie Fule} and Chunsheng He and Abdulmottaleb Zetrini and Tian Zhang and Amin Ghavaminejad and Rauth, {Andrew M.} and Henderson, {Jeffrey T.} and Wu, {Xiao Yu}",

note = "Funding Information: This work is supported in part by the Weston Brain Institute Transformational Grant, University of Toronto Connaught Innovation Award, Killam Research Fellowship by the Canada Council for the Arts, Project Grants from the Canadian Institutes of Health Research, Discovery and Equipment Grants from the Natural Sciences and Engineering Research Council of Canada, JDRF International, and Hemsley Charitable Trust Grants to X.Y.W. The authors also acknowledge the University of Toronto Connaught International Scholarship for Doctoral Students and the Pfizer Canada Graduate Fellowship in Pharmaceutical Sciences to T.A., the Centre for Collaborative Drug Research Graduate Student Incentive Fund to X.Y.W., the Ontario Graduate Scholarship (OGS) to B.L. and T.Z., the Queen Elizabeth Award to B.L. and H.Y.L., the Pharmaceutical Sciences Graduate Student Association Fellowship to E.P., King Abdulaziz City for Science and Technology (KACST) for the scholarship to I.A., Libyan Ministry of Higher Education scholarship to A.Z., Mitacs Accelerate Intership to F.J.L., the BBDC Seller Fellowship to A.GN., and the Mitacs Accelerate Fellowship to K.C. Publisher Copyright: {\textcopyright} 2022 American Chemical Society. All rights reserved.",

year = "2022",

month = jun,

day = "6",

doi = "10.1021/acs.molpharmaceut.2c00038",

language = "English (US)",

volume = "19",

pages = "1722--1765",

journal = "Molecular Pharmaceutics",

issn = "1543-8384",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - Advances in Nanomedicine Design

T2 - Multidisciplinary Strategies for Unmet Medical Needs

AU - Ahmed, Taksim

AU - Liu, Fuh Ching Franky

AU - Lu, Brian

AU - Lip, Hoyin

AU - Park, Elliya

AU - Alradwan, Ibrahim

AU - Liu, Jackie Fule

AU - He, Chunsheng

AU - Zetrini, Abdulmottaleb

AU - Zhang, Tian

AU - Ghavaminejad, Amin

AU - Rauth, Andrew M.

AU - Henderson, Jeffrey T.

AU - Wu, Xiao Yu

N1 - Funding Information: This work is supported in part by the Weston Brain Institute Transformational Grant, University of Toronto Connaught Innovation Award, Killam Research Fellowship by the Canada Council for the Arts, Project Grants from the Canadian Institutes of Health Research, Discovery and Equipment Grants from the Natural Sciences and Engineering Research Council of Canada, JDRF International, and Hemsley Charitable Trust Grants to X.Y.W. The authors also acknowledge the University of Toronto Connaught International Scholarship for Doctoral Students and the Pfizer Canada Graduate Fellowship in Pharmaceutical Sciences to T.A., the Centre for Collaborative Drug Research Graduate Student Incentive Fund to X.Y.W., the Ontario Graduate Scholarship (OGS) to B.L. and T.Z., the Queen Elizabeth Award to B.L. and H.Y.L., the Pharmaceutical Sciences Graduate Student Association Fellowship to E.P., King Abdulaziz City for Science and Technology (KACST) for the scholarship to I.A., Libyan Ministry of Higher Education scholarship to A.Z., Mitacs Accelerate Intership to F.J.L., the BBDC Seller Fellowship to A.GN., and the Mitacs Accelerate Fellowship to K.C. Publisher Copyright: © 2022 American Chemical Society. All rights reserved.

PY - 2022/6/6

Y1 - 2022/6/6

N2 - Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. First-hand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine- and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.

AB - Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. First-hand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine- and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.

KW - blood-brain barrier (BBB)-penetrating

KW - multitargeted drug delivery

KW - nanomedicine

KW - polymer lipid hybrid nanoparticles (PLN)

KW - stimulus-responsive drug release

KW - synergistic drug combination

KW - tumor microenvironment modulation

UR - http://www.scopus.com/inward/record.url?scp=85131560483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131560483&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.2c00038

DO - 10.1021/acs.molpharmaceut.2c00038

M3 - Review article

C2 - 35587783

AN - SCOPUS:85131560483

SN - 1543-8384

VL - 19

SP - 1722

EP - 1765

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

IS - 6

ER -

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this